CPR enters its May 6 Q1 sales update with short sellers building steadily and the founding family sending mixed signals — the most intriguing tension the stock has presented this month.
Short interest has climbed to 9.7% of the free float, a fresh six-week high. Bears have added roughly 1.1 percentage points since early April, when the position was running at 8.5%. That is a meaningful build in a matter of weeks and leaves CPR among the more heavily shorted names in the European beverages space. Days-to-cover is 12.2, a figure that ranks in the 8th percentile — meaning shorts would need significant time to exit in any disorderly move. The borrow market is tighter than it was a month ago: availability has come in materially and the ORTEX short score has edged up to 72.2, near the upper end of its recent range and consistent with a market that is leaning bearish on the name.
Cost-to-borrow tells a more volatile story. The rate spiked to over 6% on April 20, a reading that stood out sharply against the sub-1% prevailing norm, before rapidly collapsing back to 0.66% by April 29 — the lowest in the 30-day window. The spike appears to have been a brief, technical dislocation rather than sustained squeeze pressure; the return to near-zero borrowing costs suggests lenders quickly re-supplied the market. Lending conditions are currently loose at the headline level, which leaves room for shorts to expand further if sentiment deteriorates.
The ownership picture adds a striking subplot. Lagfin S.C.A. — the founding Garavoglia family vehicle that controls 52.3% of Campari — bought aggressively in late March across multiple tranches, accumulating net across five price levels between €4.2 and €5.4 per share. Less than three weeks later, on April 17, Lagfin reversed course and sold 299,000 shares across three transactions priced between €4.6 and €5.0. The 90-day net is firmly positive at over 4 million shares worth roughly $27.7 million, suggesting the March buying was at scale, but the April selling — at prices that have since been exceeded — introduces some ambiguity about the family's near-term conviction. The stock has recovered since those sales, closing April 29 at €6.16, about 20-30% above the average prices at which the family transacted.
The Street retains a constructive tilt. The mean analyst price target is €7.09, implying roughly 13% upside from current levels. CPR has added just 0.4% over the past month but is up 13.2% year-to-date, outpacing many consumer staples peers. Valuation has edged lower: the P/E is now 19.0x and the EV/EBITDA is 11.9x, both slightly softer on the week, which reduces one friction point for buyers. The ORTEX analyst recommendation differential ranks in the 53rd percentile — broadly neutral. EPS surprise history, however, is weak, ranking at just the 7th percentile, which means CPR has a track record of disappointing versus consensus.
Earnings history underscores that weakness. The most recent result — the April 16 announcement — produced only a 0.8% one-day gain but a 4.8% decline over the following five days. The March 4 full-year release was a different story entirely: the stock jumped almost 10% on the day and held 6.3% higher over five sessions, the kind of reaction that reflects material positive surprise. With two very different outcomes from the last two prints, there is little clear pattern to anchor expectations heading into May 6. Peer performance this week was broadly negative: DGE fell 3.0%, RI dropped 5.4%, and BF.B was the standout laggard, off over 12% on the week. Against that backdrop, CPR's 2.7% weekly decline looks comparatively contained.
The May 6 Q1 sales update is the immediate focal point — a release against which the recent short build, the conflicting family trades, and a below-average earnings-surprise track record will all be measured.
See the live data behind this article on ORTEX.
Open CPR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
